ASCVD Incretin Step-Therapy Criteria Pack

A ready-to-deploy utilization-management policy module for PBMs and health plans that uses the new noninferiority-without-superiority cardiovascular evidence to place the typically lower-priced dulaglutide first for members with type 2 diabetes and established heart disease, with defined exceptions for weight-priority patients.